Novavax Analysts Declare Covid-19 Vaccine Best in Class

Novavax shares gained 16% Friday as the biotech’s biggest bulls on Wall Street said its Covid-19 vaccine was best in class following updated results showing its effectiveness. It’s a “vaccine for the masses,” wrote B. Riley analyst Mayank Mamtani, who has a Street-high price target of $397.

• “100% protection against severe disease represented the most incremental takeaway relative to the previously reported interim analysis,”Mamtani wrote
• Cantor Fitzgerald also called the results best-in-class, writing “these data could be used for global licensure, in addition to supporting the soon-to-be completed UK EUA filing”
• Bloomberg Intelligence’s Sam Fazeli said: “The ...